Blackstone Life Sciences announced that it will lead a $350 million royalty and equity investment in Reata Pharmaceuticals as it works on a potential therapy for a rare Alport syndrome and other rare and serious forms of kidney disease.
The investment is to fund the development and potential commercialization of bardoxolone methyl -- an investigational once-daily oral therapy being studied for life-threatening diseases with few or no effective therapies approved by the U.S. Food and Drug Administration.
“This investment aligns with Blackstone Life Sciences’ mission to help advance promising new medicines to patients . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
